BIG against breast cancer small Pink Ribbon
 Think BIG News
 16 October 2013
BIG against breast cancer is proud of the pioneering work that our researchers do every day. Throughout this year, our leaders have been recognised for excellence, and we would like to congratulate them here for their awards and accolades.  In this newsletter we recognise the achievements of our founders, the BIG Chair and Vice-Chair.  Needless to say, countless other BIG leaders have received awards this year and we congratulate them for their achievements!
We also provide you with an insight into personalised medicine, and how BIG intends to address this important scientific trend through our new molecular screening programme.
Dr. Aron Goldhirsch
Dr Aron Goldhirsch
BIG was very proud that our Vice-Chair Dr. Aron Goldhirsch was presented with the St. Gallen Breast Cancer Award 2013 to honour his outstanding work in breast cancer research. Dr. Goldhirsch was involved with the definition of the scientific program of the majority of the St. Gallen Breast Cancer Conferences. Since 1988, he has co-chaired all of their closing consensus sessions.
Dr. Martine Piccart
Karnofsky award Once again, BIG was proud to see one of our leaders honoured for her work. Dr. Martine Piccart, Chair of BIG, was the 2013 Recipient of the David A. Karnofsky Memorial Award and Lecture, awarded by the American Society of Clinical Oncologists (ASCO).
Upon receiving the news of her award, Dr. Piccart said, "My immediate thoughts were for my colleagues from BIG: without their support and their trust in my vision for a strong international network of academic groups and their centres committed to 'driving' the breast cancer clinical and translational research agenda, I would never have been selected for this prestigious scientific honour."
DNA Image
Towards Personalised Medicine:  Support for Molecular Screening
We are quickly moving towards an era of personalised medicine in breast cancer, with the ultimate goal of making tumour-specific "molecular fingerprints" possible.  These fingerprints would consist of distinct genetic markers obtained from a simple blood draw or tumour sample, and would allow the physician to refine a patient's prognosis and select the best possible therapeutic options, maximising response and minimising toxicity.

Would you like to forward this email to a friend? Click here.

Share This Email: Facebook Twitter Digg Myspace Linked In Delicious
Remove my name from all future email correspondence
Address postal inquiries to:
Boulevard de Waterloo 121
Powered By
eTapestry     Delivra